Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, testified before the U.S. Senate on Tuesday, May 12, and said the Trump administration had accelerated its response to the CCP  Virus “right from the very beginning,” reaffirming there was no confrontational relationship with the president.

Sen. Richard Burr (R-N.C.) asked Fauci, “Has anybody in this administration ever asked you or any member to take the foot off the gas of trying to find a cure or any type of countermeasure?”
“No, Senator, not at all,” Fauci said. “As a matter of fact, we at NIH [National Institiutes of Health], as you know, have right from the very beginning put our foot right on that accelerator in every aspect, including the development of vaccines and therapeutics.”

“And as I described my opening statement, we actually started that in January, literally days after the virus was known and its sequence was published,” Fauci continued. “So no, I have never been told by anyone to hold back on the development of any countermeasure or any basic research project that we’ve been involved in.”

Fauci, Centers for Disease Control and Prevention (CDC) Director Robert Redfield, Food and Drug Administration (FDA) Commissioner Stephen Hahn, and Assistant Secretary for Health Brett Giroir all gave statements attesting to a relationship with President Trump that was non-confrontational, and the president readily listens to scientific advice, reported the Daily Wire.

Their statements came in response to a question from Sen. Kelly Loeffler (R-Ga.), who asked, “The mainstream media and indeed some of my colleagues in the Senate seem to want to paint each of your relationships with our president during this wartime effort as confrontational and lacking consensus. Can you categorically say here to the American people today whether this is true or untrue?”

During his address, Fauci also pointed out the speed of the development of a vaccine by the NIH, was the fastest ever achieved to get to a Phase 1 trial.

“The NIH trial moved very quickly,” Fauci said. “On January 10th, the sequence was known. On January 11th, the Vaccine Research Center met to develop a plan. On the 14th of January, we officially started the vaccine development. 62 days later, we are now in Phase I clinical trial with the two doses already fully enrolled. There will be animal safety. The Phase I will directly go into Phase II-III in late spring and early summer. If we are successful, we hope to know that in the late fall and early winter.”

 

“There are some important issues, however, in COVID-19 vaccine development,” Fauci continued. “We have many candidates and hope to have multiple winners. In other words, it’s multiple shots on goal. This will be important because this will be good for global availability if we have more than one successful candidate. We also, as the chairman mentioned, will be producing vaccine at risk, which means we’ll be investigating considerable resources in developing doses even before we know any given candidate or candidates work.”

Join our program